Skip to Content

Crisaborole

Pronunciation

(kris a BOR ole)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Ointment, External:

Eucrisa: 2% (60 g) [contains edetate calcium disodium, propylene glycol]

Brand Names: U.S.

  • Eucrisa

Pharmacologic Category

  • Phosphodiesterase-4 Enzyme Inhibitor, Topical
  • Topical Skin Product

Pharmacology

Inhibits phosphodiesterase 4 (PDE-4) and results in increased intracellular cyclic adenosine monophosphate (cAMP) levels.

Metabolism

Hepatic to 2 inactive metabolites via hydrolysis and oxidation

Protein Binding

97%

Use: Labeled Indications

Atopic dermatitis: Topical treatment of mild to moderate atopic dermatitis in patients ≥2 years of age

Contraindications

Hypersensitivity to crisaborole or any component of the formulation

Dosing: Adult

Atopic dermatitis: Topical: Apply a thin film to affected area(s) 2 times daily.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Atopic dermatitis: Topical: Children ≥2 years and Adolescents: Refer to adult dosing.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer's labeling.

Administration

For topical use only; not for ophthalmic, oral, or intravaginal use.

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Drug Interactions

Riociguat: Crisaborole may enhance the hypotensive effect of Riociguat. Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension. Monitor therapy

Adverse Reactions

1% to 10%: Local: Application site pain (4%)

<1% (Limited to important or life-threatening): Hypersensitivity reaction, urticaria

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions have been reported, including contact urticaria. Severe pruritus, swelling, or erythema (at the application site or at a distant site) may be indicative of hypersensitivity. Discontinue immediately for signs of hypersensitivity.

Monitoring Parameters

Signs of hypersensitivity

Pregnancy Considerations

Adverse effects were not observed in animal reproduction studies, except with high oral doses which also produced maternal toxicity.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience burning or stinging. Have patient report immediately to prescriber severe application site irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Hide